391668-77-2

Usage

Uses

Used in Pharmaceutical Industry:
(5-Formyl-thiazol-2-yl)-carbamic acid tert-butyl ester is used as a reagent or intermediate in the synthesis of various organic compounds for its versatile reactivity and unique structural properties. It is particularly valuable in the development of new pharmaceuticals due to its potential to contribute to the creation of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, (5-Formyl-thiazol-2-yl)-carbamic acid tert-butyl ester serves as a key intermediate in the production of agrochemicals, including pesticides and other crop protection agents. Its unique chemical structure allows for the development of effective compounds that can protect crops from pests and diseases.
Used in Medicinal Chemistry Research:
(5-Formyl-thiazol-2-yl)-carbamic acid tert-butyl ester is utilized as a subject of interest in medicinal chemistry research. Scientists explore its biological activity and potential therapeutic applications, aiming to discover new treatments and drugs that can benefit human health.
Overall, (5-Formyl-thiazol-2-yl)-carbamic acid tert-butyl ester is a versatile and significant chemical compound with a wide range of industrial and scientific applications, particularly in the development of pharmaceuticals, agrochemicals, and as a subject of research for new therapeutic discoveries.

InChI:InChI=1/C9H12N2O3S/c1-9(2,3)14-8(13)11-7-10-4-6(5-12)15-7/h4-5H,1-3H3,(H,10,11,13)

Upstream product

• 302964-01-8 ethyl 2-[(tert-butoxycarbonyl)amino]-1.3-thiazole-5-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 68-12-2 N,N-dimethyl-formamide 
• 170961-15-6 tert-butyl 1,3-thiazole-2-yl-carbamate 
• 1001419-37-9 tert-butyl [5-(hydroxymethyl)-1,3-thiazol-2-yl]carbamate 
• 1003-61-8 2-aminothiazole-5-carbaldehyde 

Downstream Products

• 920313-27-5 2-amino-5-formylthiazole hydrochloride 
• 1206478-61-6 C₂₇H₂₅N₅OS₂ 
• 878376-15-9 tert-butyl [5-({[(3-fluorophenyl)sulfonyl]amino}methyl)-1,3-thiazol-2-yl]carbamate 
• 878376-14-8 tert-butyl (5-{[(3-fluorobenzoyl)amino]methyl}-1,3-thiazol-2-yl)carbamate 
• 878376-12-6 tert-butyl {5-[(E)-(hydroxyimino)methyl]-1,3-thiazol-2-yl}carbamate 

Relevant academic research and scientific papers

Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects

The BCR-ABL fusion oncoprotein causes chronic myeloid leukemia or acute lymphoblastic leukemia in Ph+ patients because the ABL kinase is constitutively activated. However, current clinical treatment with ABL inhibitors is seriously limited by drug resistance and adverse effects. Although the emerging proteolysis-Targeting chimeras (PROTACs) have been introduced to degrade BCR-ABL, most of them showed limited activity and could not overcome the common drug-resistant mutants, especially for T315I mutant. Herein, we systematically designed a set of unique PROTACs by globally targeting all the three binding sites of BCR-ABL, including dasatinib-, ponatinib-, and asciminib-based PROTACs. Our ponatinib-based PROTACs showed practical activity as dasatinib-based PROTACs, while no reported ponatinib-based PROTACs could degrade BCR-ABL before. As a proof of concept, some additional dasatinib-based PROTACs were then designed to degrade T315I mutant too. We provided a global PROTAC toolbox for degrading both wild-Type and T315I-mutated BCR-ABL from each binding site. More importantly, these PROTACs showed better selectivity and less adverse effects than the inhibitors, indicating that PROTACs had great potential for overcoming clinical drug resistance and safety issues.

NOVEL COMPOUNDS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE

The present invention relates to novel Tricyclic Spirocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Spirocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or aired fasting glucose.

HYDRAZONE DERIVATIVE

A hydrazone derivative of formula [I]: wherein Ring A is aryl or heteroaryl, Ring T is heteroaryl or heterocycle, R1 and R2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl, etc., R3 and R4 comb

Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, —C(O)—, —C(N—OR5)—, —C(N—OR5)—CH(R6)—, —CH(R6)—C(N—OR5)—, —O—, —OCH2—, —CH2O— or —S(O)0-2—; Y is —O—, —(CH2)2—, —C(═O)—, —C(═NOR7)— or —SO0-2—; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combination with other agents.

Thienopyrimidines useful as Aurora kinase inhibitors

The present invention provides compounds having the formula: wherein R1, R2, X1, X2, L1, L2, Y and Z are as defined in classes and subclasess herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.

SILICON COMPOUNDS AND THEIR USE

A compound of formula (1): wherein A is -CH2CH2-, -CH=CH- or -C=-C-; B is aryl or heteroaryl; D is optionally present and is -C(O)-, -C(O)NH-, -C(O)CH2- or -C(O)CH2- O-; E is optionally present and is alkylene or heteroarylene; R1 is hydrogen or alkyl; R2 is hydrogen, alkyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; R3 and R4 are the same or different and are each hydrogen, alkyl or cycloalkyl; and each R5 is the same or different and is alkyl, -alkyl-aryl or -alkyl-cycloalkyl, or R5-Si-R5 taken together form heterocycloalkyl; or a pharmaceutically acceptable salt thereof.

MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE

Compounds having a high conductance-type of calcium-activated K channel opening effect and a smooth muscle relaxant effect for bladder based on the K-channel opening effect, which can be used in treating pollakiuria and urinary incontinence, are provided. 3,5-Dicyanopyridine derivatives or their salts.

Medicine comprising dicyanopyridine derivative

Compounds having a high conductance-type of calcium-activated K channel opening effect and a smooth muscle relaxant effect for bladder based on the K-channel opening effect, which can be used in treating pollakiuria and urinary incontinence, are provided.